PureTech Health (NASDAQ:PRTC) Stock Price Up 2% – What’s Next?

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) rose 2% on Thursday . The company traded as high as $19.11 and last traded at $19.05. Approximately 1,237 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 2,999 shares. The stock had previously closed at $18.67.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

PureTech Health Trading Down 2.7%

The company has a 50 day moving average of $17.49 and a 200 day moving average of $17.55.

Institutional Trading of PureTech Health

Several hedge funds have recently added to or reduced their stakes in PRTC. Lansdowne Partners UK LLP purchased a new position in PureTech Health in the third quarter worth approximately $260,973,000. Pentwater Capital Management LP raised its holdings in shares of PureTech Health by 50.0% in the 3rd quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock valued at $1,388,000 after purchasing an additional 25,000 shares in the last quarter. Diadema Partners LP purchased a new stake in shares of PureTech Health during the 2nd quarter worth $126,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of PureTech Health during the second quarter worth $29,000. Institutional investors and hedge funds own 0.04% of the company’s stock.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.